Administer ABLAVAR^® as an intravenous bolus injection, manually or by power injection, at a dose of 0.12 mL/kg body weight (0.03 mmol/kg) over a period of time of up to 30 seconds followed by a 25-30 mL normal saline flush. (See Table 1 for weight-adjusted dose volumes). See full Prescribing Information for information on special patient populations, including patients with renal insufficiency.

Inspect the ABLAVAR^® vial visually for particulate matter and discoloration prior to administration. Do not use the solution if it is discolored or particulate matter is present.

ABLAVAR^® is intended for single use only and should be used immediately upon opening. Discard any unused portion of the ABLAVAR^® vial.

Do not mix intravenous medications or parenteral nutrition solutions with ABLAVAR^®. Do not administer any other medications in the same intravenous line simultaneously with ABLAVAR^®.

TABLE 1. Weight-Adjusted Volumes for the 0.03 mmol/kg Dose¹
Body Weight		Volume
Kilograms (kg)	Pounds (lb)	Milliliters (mL)
40	88	4.8
50	110	6.0
60	132	7.2
70	154	8.4
80	176	9.6
90	198	10.8
100	220	12.0
110	242	13.2
120	264	14.4
130	286	15.6
140	308	16.8
150	330	18.0
160	352	19.2

ABLAVAR^® Dosage Forms and Strengths¹

Each mL of ABLAVAR^® contains 244 mg/mL gadofosveset trisodium (equivalent to 0.25 mmol/mL) and is available in 10-mL and 15-mL single-use vials.

ABLAVAR^® Dosing Calculations

Always verify patient's weight [kg] and total dose [mL] prior to injecting.

Weight Conversion to Kilograms²	Example Weight Conversion to Kilograms


ABLAVAR^® Dose Calculation¹	Example ABLAVAR^® Dose Calculation
0.12 mL/kg * Weight in kg = Total dose in mL	0.12 mL/kg * 70 kg = 8.4 mL

Dose Calculator
Enter patient weight and select from kg or lb. Press calculate button.

Reference

1. ABLAVAR^® [package insert]. North Billerica, MA: Lantheus Medical Imaging, Inc.; 2011. 2. National Institute of Standards and Technology (NIST) web site. http://www.nist.gov/pml/wmd/metric/common-conversion.cfm. Accessed May 18, 2011.

INDICATIONS:

ABLAVAR^® is indicated for use as a contrast agent in magnetic resonance angiography (MRA) to evaluate aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease.

CONTRAINDICATIONS:

History of a prior allergic reaction to a gadolinium-based contrast agent.

IMPORTANT SAFETY INFORMATION:

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)

Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.

The risk for NSF appears highest among patients with:

chronic, severe kidney disease (GFR < 30 mL/min/1.73m²), or
acute kidney injury.

Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (e.g. age > 60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing.
For patients at highest risk for NSF, do not exceed the recommended ABLAVAR dose and allow a sufficient period of time for elimination of the drug from the body prior to re-administration.

ABLAVAR^® Injection: As with other contrast media, the possibility of serious or life-threatening anaphylactic or anaphylactoid reactions, including cardiovascular, respiratory and/or cutaneous manifestations, should always be considered. As with other gadolinium based contrast agents, caution should be exercised in patients with renal insufficiency due to the possibility of further deterioration in renal function.

In clinical trials, a small increase (2.8 msec) in the average change from baseline in QTc was observed at 45 minutes following ABLAVAR^® administration. These QTc prolongations were not associated with arrhythmias or symptoms. Caution should be used in patients at high risk for arrhythmias due to baseline QTc prolongation.

Have emergency resuscitative equipment available prior to and during ABLAVAR^® administration.

Please see full Prescribing Information, including boxed WARNING regarding Nephrogenic Systemic Fibrosis (NSF).

ABLAVAR® Dosage Forms and Strengths1